2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. (September 2015) - Nakamura, M.; Yuki, S.; Nakatsumi, H.; Muto, O.; Hosokawa, A.; Kato, T.; Iwanaga, I.; Hatanaka, K.; Tsuji, Y.; Sato, A.; Eto, K.; Furukawa, K.; et al.